Your browser doesn't support javascript.
loading
Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial.
Valiengo, Leandro da Costa Lane; Goerigk, Stephan; Gordon, Pedro Caldana; Padberg, Frank; Serpa, Mauricio Henriques; Koebe, Stephanie; Santos, Leonardo Afonso Dos; Lovera, Roger Alberto Marcos; Carvalho, Juliana Barbosa de; van de Bilt, Martinus; Lacerda, Acioly L T; Elkis, Helio; Gattaz, Wagner Farid; Brunoni, Andre R.
Afiliación
  • Valiengo LDCL; Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Goerigk S; Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
  • Gordon PC; Department of Psychological Methodology and Assessment, Ludwig Maximilian University of Munich, Munich, Germany.
  • Padberg F; Hochschule Fresenius, University of Applied Sciences, Munich, Germany.
  • Serpa MH; Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Koebe S; Department of Neurology and Stroke, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Santos LAD; Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.
  • Lovera RAM; Laboratory of Neuroimaging (LIM-21), Department and Institute of Psychiatry, Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Carvalho JB; Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • van de Bilt M; Instituto Bairral de Psiquiatria, Itapira, Brazil.
  • Lacerda ALT; Instituto Bairral de Psiquiatria, Itapira, Brazil.
  • Elkis H; Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Gattaz WF; Laboratory of Neurosciences (LIM-27), Department and Institute of Psychiatry, Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN), Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Brunoni AR; Programa de Transtornos Afetivos, Laboratório Interdisciplinar de Neurociências Clínicas, Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil.
JAMA Psychiatry ; 77(2): 121-129, 2020 02 01.
Article en En | MEDLINE | ID: mdl-31617873
ABSTRACT
Importance Negative symptoms represent a substantial burden in schizophrenia. Although preliminary studies have suggested that transcranial direct current stimulation (tDCS) is effective for some clusters of symptoms, the clinical benefits for negative symptoms are unclear.

Objective:

To determine the efficacy and safety of tDCS vs sham as an add-on treatment for patients with schizophrenia and predominant negative symptoms. Design, Setting, and

Participants:

The double-blind Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) randomized clinical trial was conducted from September 2014 to March 2018 in 2 outpatient clinics in the state of São Paulo, Brazil. Patients with schizophrenia with stable negative and positive symptoms and a minimum score of 20 points in the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS) were included.

Interventions:

Ten sessions of tDCS performed twice a day for 5 days or a sham procedure. The anode and the cathode were positioned over the left prefrontal cortex and the left temporoparietal junction, respectively. Main Outcomes and

Measures:

Change in the PANSS negative symptoms subscale score at week 6 was the primary outcome. Patients were followed-up for an additional 6 weeks.

Results:

Of the 100 included patients, 20 (20.0%) were female, and the mean (SD) age was 35.3 (9.3) years. A total of 95 patients (95.0%) finished the trial. In the intention-to-treat analysis, patients receiving active tDCS showed a significantly greater improvement in PANSS score compared with those receiving the sham procedure (difference, 2.65; 95% CI, 1.51-3.79; number needed to treat, 3.18; 95% CI, 2.12-6.99; P < .001). Response rates for negative symptoms (20% improvement or greater) were also higher in the active group (20 of 50 [40%]) vs the sham group (2 of 50 [4%]) (P < .001). These effects persisted at follow-up. Transcranial direct current stimulation was well tolerated, and adverse effects did not differ between groups, except for burning sensation over the scalp in the active group (43.8%) vs the sham group (14.3%) (P = .003). Conclusions and Relevance Transcranial direct current stimulation was effective and safe in ameliorating negative symptoms in patients with schizophrenia. Trial Registration ClinicalTrials.gov identifier NCT02535676.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia / Estimulación Transcraneal de Corriente Directa Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Humans / Male Idioma: En Revista: JAMA Psychiatry Año: 2020 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia / Estimulación Transcraneal de Corriente Directa Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Humans / Male Idioma: En Revista: JAMA Psychiatry Año: 2020 Tipo del documento: Article País de afiliación: Brasil